Equity Overview
Price & Market Data
Price: $2.28
Daily Change: +$0.09 / 3.95%
Daily Range: $2.28 - $2.28
Market Cap: $176,451,904
Daily Volume: 6,045
Performance Metrics
1 Week: 4.78%
1 Month: -16.41%
3 Months: 22.35%
6 Months: -9.88%
1 Year: -6.41%
YTD: 21.67%
Company Details
Employees: 226
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.